The Cutting-Edge World Of Proteomics – And What Investors Need To Know
There’s a new type of revolutionary science on the horizon: proteomics. But just what is proteomics – and what do healthcare investors need to know…
Biotech Investors
Biotech Opportunities And Risks In Q2 – And Beyond
After a challenging first quarter of 2021 for biotech investors, what does the second quarter – and, beyond that, the second half of 2021 –…
PDUFA Dates: “Make-Or-Break Catalysts” For Biotech Stocks In October
Drugs for pain management, migraines, dry eye disease and Ebola are among those with PDUFA dates – deadlines by which the FDA must review new…
Why This Biotech’s Mixed Clinical Results Shouldn’t Discourage Investors With A High Risk Tolerance
The small-cap biotech highlighted in today’s article has had mixed clinical results when it comes to one of its novel cancer immunotherapy candidates. The author,…